Synapse - Ariela Noy

Search Within

Ariela Noy

Results (373)

Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

Journal Article

Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Gerecitano, J. F.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
European Journal of Cancer (2020)

Fulltext@MSK | Save

A multicenter, open-label feasibility study of daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic lymphoma: AIDS Malignancy Consortium 105

Meeting Abstract

Tan, C. R.; Barta, S. K.; Lensing, S. Y.; Noy, A.
Blood (2019)

Fulltext@MSK | Save

Comparative analysis of immune reconstitution in HIV-positive recipients of allogeneic and autologous stem cell transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 trials

Meeting Abstract

Shindiapina, P.; Pietrzak, M.; Seweryn, M.; McLaughlin, E.; Zhang, X.; Makowski, M.; Lyberger, J.; Chang, H.; Ahmed, E. H.; Prouty, A.; more...
Blood (2019)

Fulltext@MSK | Save

Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Meeting Abstract

Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

A randomized trial of EPOCH-based chemotherapy with vorinostat for highly aggressive HIV-associated lymphomas: Updated results evaluating impact of diagnosis-to-treatment interval (DTI) and pre-protocol systemic therapy on outcomes

Meeting Abstract

Ramos, J. C.; Sparano, J.; Moore, P. C.; Siegel, E.; Lee, J. Y.; Reid, E. G.; Ambinder, R. F.; Chadburn, A.; Rubinstein, P. G.; Durand, C.; more...
Blood (2019)

Fulltext@MSK | Save

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma

Meeting Abstract

Ramos, J. C.; Ambinder, R. F.; Sparano, J.; Lee, J. Y.; Kaplan, L. D.; Wachsman, W.; Aboulafia, D. M.; Noy, A.; Ratner, L.; Henry, D. H.; more...
Blood (2019)

Fulltext@MSK | Save

A phase II clinical trial of CPI-613 (devimistat) in patients with relapsed or refractory burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2and/or BCL6

Meeting Abstract

Noy, A.; Pardee, T. S.; Nikolaenko, L.; Steiner, R. E.; Abramson, J. S.; Dunleavy, K.; Luther, S.
Blood (2019)

Fulltext@MSK | Save

Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
Blood (2019)

Fulltext@MSK | Save

High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
Blood (2019)

Fulltext@MSK | Save

Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma

Meeting Abstract

Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
Blood (2019)

Fulltext@MSK | Save